In a patient with acute renal insufficiency, which medication should be discontinued: Cardiol (amlodipine), hydrochlorothiazide, atorvastatin, duloxetine, or oxycodone?

Hydrochlorothiazide Should Be Discontinued

In a patient with acute renal insufficiency, hydrochlorothiazide is the medication that should be discontinued among the options provided. The ESC guidelines explicitly state that when renal impairment occurs with concomitant loop and thiazide diuretic use, the thiazide diuretic should be stopped 1.

Rationale for Discontinuing Hydrochlorothiazide

The guidelines provide a clear algorithmic approach to managing renal impairment:

• First-line action: Check for hypovolemia/dehydration and exclude nephrotoxic agents
• If using both loop and thiazide diuretics: Stop the thiazide diuretic 1
• Thiazides become ineffective when GFR falls below 30 mL/min and can worsen renal function through volume depletion 2

Research evidence supports this recommendation, showing that exercise-induced acute renal failure can be precipitated by hydrochlorothiazide, particularly when combined with conditions causing decreased renal blood flow 3.

Why Other Medications Can Be Continued (With Caution)

Cardiol (Amlodipine)

• Calcium channel blockers are not nephrotoxic and do not require discontinuation in acute renal insufficiency
• The guidelines only recommend reconsidering CCBs for symptomatic hypotension, not for renal impairment 1

Atorvastatin

• Does not require discontinuation for acute renal insufficiency
• FDA labeling identifies renal impairment as a risk factor for myopathy but does not mandate discontinuation 4
• Should be temporarily discontinued only if the patient develops severe conditions at high risk for rhabdomyolysis-induced renal failure (sepsis, shock, severe hypovolemia) 4
• Recent research shows atorvastatin-associated AKI is primarily a concern in specific populations (AMI, ischemic stroke, elderly) rather than general acute renal insufficiency 5

Duloxetine

• While case reports exist of duloxetine-associated AKI 6, there is no guideline recommendation to discontinue SNRIs in acute renal insufficiency
• Dose adjustment may be needed in severe renal impairment, but discontinuation is not routinely required

Oxycodone

• Can be continued with dose reduction in renal impairment 7, 8
• Research indicates oxycodone should be used with caution and reduced doses in renal dysfunction, but it is not contraindicated 8
• Unlike morphine and codeine (which should be avoided), oxycodone is considered safer with appropriate monitoring 7

Clinical Algorithm for Acute Renal Insufficiency

When managing medications in acute renal insufficiency:

1. Immediately discontinue: Thiazide diuretics (hydrochlorothiazide) if on combination diuretic therapy 1
2. Assess for reversible causes: NSAIDs, hypovolemia, hypotension, urinary obstruction 9
3. Consider dose reduction (not discontinuation): ACE inhibitors/ARBs, loop diuretics, opioids 9
4. Continue without change: Calcium channel blockers, statins (unless rhabdomyolysis risk)
5. Monitor closely: Electrolytes, creatinine, volume status 9

Important Caveats

• Do not discontinue ACE inhibitors/ARBs reflexively: Recent evidence shows discontinuation is associated with worse outcomes, including increased mortality 10, 11. The guidelines recommend dose reduction rather than discontinuation unless creatinine exceeds 250 μmol/L or increases >50% from baseline 9

• Thiazides are specifically problematic because they become ineffective at lower GFR levels and can exacerbate volume depletion, worsening prerenal azotemia

• Ensure clear communication about medication changes and when to restart discontinued medications to prevent unintentional harm 12